Nephron Research upgraded Medtronic (MDT) to Buy from Hold with a $120 price target The firm says the company’s pickup in growth “has legs.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Medtronic’s Strategic Advancements and Early FDA Approval of Hugo Boost Buy Rating
- Medtronic’s Strategic Moves and Market Position: Balancing Growth Prospects with Current Valuation
- Medtronic’s Cautious U.S. Market Entry with HUGO: Hold Rating Amid Uncertain Impact
- Medtronic announces clearance of Hugo RAS by FDA for urological procedures